Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
-
+
P11 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Clinical Trials in Progress
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
- Presentations: 3
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P11.03 - SHR-1316 in Combination With Fluzoparib in Relapsed Small-Cell Lung Cancer: An Open-Label, Multicenter, Two-Stage, Phase Ⅰb Trial
00:00 - 00:00 | Presenter: Yun Fan
- Abstract
Loading...
-
+
P19 - Immunotherapy (Phase II/III Trials) - Previously Treated NSCLC
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 2
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P19.01 - RATIONALE-303 Phase 3 Tislelizumab vs Docetaxel in Previously Treated Advanced NSCLC: China Subgroup Analysis
00:00 - 00:00 | Presenter: Yun Fan
- Abstract
Loading...
-
+
P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 18
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P45.08 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading...
-
+
P59 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - Targeted Therapies Biomarkers
- Type: Posters
- Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
- Presentations: 32
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P59.08 - Identifying the Origin of Lung-Specific Cancer of Unknown Primary Based on Comprehensive Genomic Profiling Optimized With DNA Methylation
00:00 - 00:00 | Author(s): Kaiyan Chen
- Abstract
Loading...
-
+
MA02 - RET and Novel Combinations of Osimertinib
- Type: Mini Oral
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 8
- Coordinates: 9/08/2021, 09:30 - 10:30, Program Auditorium
-
+
MA02.02 - Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer
09:35 - 09:40 | Presenter: Qing Zhou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
WS06 - Joint IASLC - CAALC - CSCO Workshop: Looking Toward the Future: Recognizing and Curing Lung Cancer
- Type: Workshop
- Track: N.A.
- Presentations: 9
- Moderators:Caicun Zhou
- Coordinates: 9/11/2021, 22:15 - 23:45, Program Auditorium
-
+
WS06.07 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
23:13 - 23:23 | Presenter: Shun Lu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation
- Type: Oral
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 6
- Moderators:Helena A Yu
- Coordinates: 9/12/2021, 18:45 - 19:45, Program Auditorium
-
+
OA15.02 - Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations
18:55 - 19:05 | Presenter: Pasi A. Janne
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?
- Type: Mini Oral
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 9
- Coordinates: 9/13/2021, 17:30 - 18:30, Program Auditorium
-
+
MA13.08 - CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
18:10 - 18:15 | Presenter: Jie Wang
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
